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Lund, Stockholm, Uppsala, and Gothenburg, Sweden; Vienna and Innsbruck, Austria; Ljubljana, Slovenia;
and Copenhagen, DenmarkObjectives The aim of this study was to conﬁrm the cardioprotective effects of hypothermia using a combination of cold
saline and endovascular cooling.Background Hypothermia has been reported to reduce infarct size (IS) in patients with ST-segment elevation myocardial
infarctions.Methods In a multicenter study, 120 patients with ST-segment elevation myocardial infarctions (<6 h) scheduled to
undergo percutaneous coronary intervention were randomized to hypothermia induced by the rapid infusion
of 600 to 2,000 ml cold saline and endovascular cooling or standard of care. Hypothermia was initiated before
percutaneous coronary intervention and continued for 1 h after reperfusion. The primary end point was IS as
a percent of myocardium at risk (MaR), assessed by cardiac magnetic resonance imaging at 4  2 days.Results Mean times from symptom onset to randomization were 129  56 min in patients receiving hypothermia and 132
 64 min in controls. Patients randomized to hypothermia achieved a core body temperature of 34.7C before
reperfusion, with a 9-min longer door-to-balloon time. Median IS/MaR was not signiﬁcantly reduced (hypothermia:
40.5% [interquartile range: 29.3% to 57.8%; control: 46.6% [interquartile range: 37.8% to 63.4%]; relative reduction
13%; p ¼ 0.15). The incidence of heart failure was lower with hypothermia at 45  15 days (3% vs. 14%, p < 0.05),
with no mortality. Exploratory analysis of early anterior infarctions (0 to 4 h) found a reduction in IS/MaR of
33% (p < 0.05) and an absolute reduction of IS/left ventricular volume of 6.2% (p ¼ 0.15).Conclusions Hypothermia induced by cold saline and endovascular cooling was feasible and safe, and it rapidly reduced
core temperature with minor reperfusion delay. The primary end point of IS/MaR was not signiﬁcantly reduced.
Lower incidence of heart failure and a possible effect in patients with early anterior ST-segment elevation
myocardial infarctions need conﬁrmation. (Efﬁcacy of Endovascular Catheter Cooling Combined With Cold Saline for
the Treatment of Acute Myocardial Infarction [CHILL-MI]; NCT01379261) (J Am Coll Cardiol 2014;63:1857–65)
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1858Contemporary therapy in pa-
tients with ongoing ST-segment
elevation myocardial infarctions
(STEMIs) is to restore blood
ﬂow in the ischemic myocardium
as soon as possible to reduce
infarct size (IS) and associated
complications. IS is one of the
main predictors of both short-
term and long-term outcomes in
patients with acute myocardial
infarction (AMI) (1,2). Reducing
IS is therefore an important
objective of current research to
improve outcomes after AMI.
Although reperfusion therapy is
a prerequisite for myocardial
salvage, the process in itself may
cause irreversible damage to themyocardium, referred to as reperfusion injury (3). In
addition to reperfusion injury, total ischemic time also
contributes to greater IS and increased mortality (4,5).
Experimental studies have shown that mild hypothermia,
induced before reperfusion of acute coronary occlusion,
reduces IS and limits microvascular injury (6–11). How-
ever, hypothermia has failed to reduce IS if initiated after
the onset of reperfusion (10–12). In animal models, hy-
pothermia before the start of ischemia can reduce IS by
100%; during ischemia, IS may be reduced by up to 80%.
Immediately at reperfusion, a 20% reduction in IS is
achieved, while hypothermia begun after reperfusion does
not reduce IS at all (10–12).Lund University, Lund, Sweden; yDepartment
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2013; revised manuscript received December 9,The 2 major clinical trials investigating mild hypothermia
using endovascular cooling as an adjunct therapy in AMI
failed to show a signiﬁcant reduction in IS (13,14). Post-hoc
analysis of those trials showed that only a minority of pa-
tients were hypothermic at the onset of reperfusion. The
subgroup of patients with anterior STEMIs who were
cooled to a temperature of 35C before reperfusion did
have signiﬁcant reductions in IS. Early and more rapidly
induced hypothermia, accomplished by a combination of
rapid infusion of cold saline together with an endovascular
cooling catheter, caused a reduction of IS only if induced
before reperfusion, not afterward (10,15). On the basis of
these animal studies, the RAPID MI-ICE (Rapid Intra-
vascular Cooling in Myocardial Infarction as Adjunctive to
Percutaneous Coronary Intervention) safety and feasibility
study was performed, in which hypothermia was induced by
a combination of infusion of cold saline and an endovascular
catheter cooling. All patients were cooled to a target tem-
perature of 35C before reperfusion, and cold saline was
safely infused to help induce hypothermia as early as possible
during the ischemic period before the initiation of endo-
vascular cooling (16). Hypothermia signiﬁcantly reduced
IS normalized to myocardium at risk (MaR) by 38%. A
pooled analysis of 2 trials, ICE-IT (Intravascular Cooling
Adjunctive to Percutaneous Coronary Intervention and
Rapid Intravascular Cooling in Myocardial Infarction as
Adjunctive to Percutaneous Coronary Intervention), that
used the Accutrol endovascular cooling catheter (Philips
Healthcare, San Diego, California) found that IS was
reduced in patients achieving temperatures of 35C before
reperfusion (13). However, these were post hoc analyses, and
a larger efﬁcacy trial was needed to conﬁrm a beneﬁcial effect
of hypothermia for patients with STEMIs.
We designed a multicenter, randomized, end point–
blinded study using central venous catheter core cooling
combined with rapidly infused cold saline as an adjunct to
percutaneous coronary intervention (PCI) for the treat-
ment of CHILL-MI (AMI: Rapid Endovascular Catheter
Core Cooling Combined With Cold Saline as an Adjunct to
Percutaneous Coronary Intervention for the Treatment of
Acute Myocardial Infarction).Methods
Ethics and organization. The study was performed in
accordance with the Declaration of Helsinki, and the local
ethics committees approved the study protocol. All patients
gave written informed consent before inclusion in the study.
The steering committee designed the trial in collabora-
tion with the sponsor and had responsibility for scientiﬁc
conduct and the presentation and publication of results. The
trial was coordinated and monitored by Uppsala Clinical
Research Center (UCR), which also managed the database
and performed the statistical analyses. An independent
data and safety monitoring board, consisting of physicians
independent of the trial sponsor and operational leadership,
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unblinded data.
Study population. From July 2011 to March 2013, 120
patients from 9 sites in 4 countries (Lund, Uppsala,
Stockholm, and Gothenburg, Sweden; Copenhagen and
Aarhus, Denmark; Vienna and Innsbruck, Austria; and
Ljubljana, Slovenia), were enrolled in this prospective,
multicenter, randomized, end point–blinded study to test
the feasibility and safety of an infusion of cold saline
together with endovascular hypothermia, using the Accutrol
catheter and InnerCool RTx endovascular console (Philips
Healthcare) as an adjunct therapy in patients with STEMIs
eligible for primary PCI. Men and women ages 18 and 75
years presenting with anterior or inferior STEMIs with
ST-segment elevation >0.2 mV in 2 contiguous leads and
a duration of symptoms <6 h were included. For inferior
STEMI, an additional ST-segment depression in 2
contiguous anterior leads for a total ST-segment deviation
(inferior ST-segment elevation plus anterior ST-segment
depression) of 0.8 mV was required. A second electro-
cardiogram was obtained in the catheterization laboratory
before randomization to ensure persistent ST-segment
elevation. Patients with cardiac arrest, previous AMIs, pre-
vious PCI or coronary artery bypass grafting, known
congestive heart failure, end-stage kidney disease or hepatic
failure, recent stroke, coagulopathy, pregnancy, or Killip
class II to IV at presentation were excluded.
Protocol. Eligible patients were randomized 1:1 to hypo-
thermia or standard of care after admission and before
coronary angiography. The randomization list was computer
generated using varying block sizes and stratiﬁcation by site.
Sealed opaque envelopes containing study group assign-
ments were opened after informed consent was obtained.
Patients assigned to hypothermia were administered 30 mg
of oral buspirone. Meperidine was administered as an
intravenous loading dose of 1 mg/kg or 0.5 mg/kg if the
patient had received morphine before enrollment in the
study. Additional 25-mg intravenous bolus doses of
meperidine were administered as needed to reduce shivering.
Hypothermia was initially induced by forced infusion of 4C
cold saline using pressure bags. Volume administered was
600 to 2,000 ml, according to a weight-adjusted schedule
(10 ml/kg for anterior STEMI and 20 ml/kg for inferior
STEMI). Before angiography, a 14-F introducer was
inserted in the femoral vein. Through the introducer, a 14-F
Accutrol catheter was placed into the inferior vena cava with
the tip of the catheter at the level of the diaphragm. The
target temperature was set to 33C. Core body temperature
was assessed using an integrated temperature sensor at the
tip of the cooling catheter, which helped minimize tem-
perature lag that occurs in other body compartments, such as
the bladder, ear, and rectum, during rapid core cooling (17).
After placement and activation of the cooling catheter,
coronary angiography and PCI were performed without
delay, except for a brief pause to measure core temperature
just before advancing the guidewire through the culpritlesion. Cooling was maintained for 1 h after reperfusion,
followed by spontaneous rewarming. If the PCI procedure
took longer than 1 h, cooling was continued until the end of
the procedure. Loading doses of 500 mg of aspirin and
adenosine diphosphate receptor blockers were given to all
patients before cardiac catheterization. Heparin, glycopro-
tein IIb/IIIa inhibitors, and bivalirudin were administered at
the discretion of the treating physician.
Cardiac magnetic resonance (CMR) imaging. After
4  2 days, patients underwent CMR examinations
(Online Appendix) (18,19).
Image analysis. The analysis of ventricular dimensions,
MaR, and IS was performed at a core laboratory (Imacor
AB, Lund, Sweden) using postprocessing software
(Segment version 1.9 R3084, Medviso, Lund, Sweden)
(Online Appendix) (18–21).
Biochemical markers. Creatine kinase–MBand troponin T
were sampled on admission to the catheterization laboratory
and at 12 and 24 h after admission. Central core laboratory
analysis was performed at UCR. Peak values were deﬁned
as the highest measured values within 24 h. The area under
the curve was calculated from the measurements. N-terminal
pro–brain natriuretic peptide was sampled on day 4  2.
Clinical endpoints. Clinical endpoints were collected using
a clinical report form during the index hospital stay, at 45
 15 days, and at 6 months. Furthermore, clinical events
were collected by adverse event and serious adverse event
reporting. Hospital charts were monitored by independent
monitors for all patients. All primary events (death and heart
failure) were evaluated independently by a blinded clinical
events committee.
Statistical analysis. On the basis of a mean IS as a percent
of MaR in the control group of 48% and a standard devia-
tion in both groups of 18% (10), 72 evaluable patients would
give 80% power to detect a 25% relative decrease in the
hypothermia group, using a 2-sided test at the 5% signiﬁ-
cance level. To account for uncertainty in variability and
dropout rate, a sample size of 120 patients was chosen,
estimated to give 90% power after 20% dropout.
All analyses were performed according to the protocol and
the statistical analysis plan, using intention to treat without
imputation of missing data. Statistical tests were performed
at the 0.05 signiﬁcance level using 2-sided alternative hy-
potheses. All statistical analyses were performed by the
statistics section at UCR using SAS version 9.3 (SAS
Institute Inc., Cary, North Carolina) (Online Appendix).
Results
One hundred twenty patients from 9 sites in 4 countries
were enrolled in the study. There were no signiﬁcant dif-
ferences in baseline characteristics between the groups
(Table 1). Mean times from onset of symptoms to
randomization were 132  64 min and 129  56 min in the
hypothermia and control groups. All but 3 patients under-
went PCI. One patient was reported as having undergone
Table 1 Clinical and Angiographic Data
Hypothermia
(n ¼ 61)
Control
(n ¼ 59)
Age, yrs 57 (37–79) 59 (30–75)
Women 13 (21%) 8 (14%)
Hypertension 17 (28%) 7 (12%)
Diabetes 8 (13%) 3 (5%)
Hyperlipidemia 10 (16%) 1 (2%)
Current smoker 28 (46%) 23 (39%)
BMI, kg/m2 28.4  4.9 27.0  3.3
Anterior STEMI 23 (38%) 28 (48%)
Inferior STEMI 38 (62%) 30 (52%)
Onset of symptoms to reperfusion, min 132  64 129  56
Randomization-to-balloon time, min 42  16 33  21
Initial TIMI ﬂow grade 0 or 1 54 (89%) 48 (81%)
Initial TIMI ﬂow grade 2 or 3 7 (11%) 11 (19%)
TIMI ﬂow grade 3 after PCI 57 (93%) 53 (90%)
Thrombectomy 35 (59%) 41 (69%)
GP IIb/IIIa inhibitors 14 (23%) 22 (34%)
Bivalirudin 35 (57%) 31 (52%)
Ticagrelor/prasugrel 54 (89%) 67 (84%)
Aspirin 61 (100%) 59 (100%)
Buspirone 30 mg 44 (71%) 0
Meperidine/pethidine, mg 114  67 0
DES 44 (75%) 50 (86%)
Values are median (range), n (%), or mean  SD. p = NS for all comparisons.
BMI ¼ body mass index; DES ¼ drug-eluting stent(s); GP ¼ glycoprotein; PCI ¼ percutaneous
coronary intervention; STEMI ¼ ST-segment elevation myocardial infarction; TIMI ¼ Thrombolysis In
Myocardial Infarction.
Figure 1
Temperature in Controls and
Hypothermia-Treated Patients
The temperatures recorded at baseline, 1.5 h after percutaneous coronary
intervention (PCI), and 6 h after PCI were recorded using a tympanic thermometer.
The temperatures at wire crossing and end of cooling were core body temperatures
recorded from the tip of the cooling catheter.
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(TIMI) ﬂow grade 3 was established in 93% and 90% of
patients, respectively. Thrombus aspiration was performed
in 59% and 69% of patients, respectively. The novel, more
potent P2Y12 inhibitors ticagrelor or prasugrel were used in
89% and 84% of patients, respectively (Table 1).
Hypothermia treatment. Baseline tympanic temperature
was similar in the 2 groups (36.0  0.7C vs. 36.0  0.7C).
After randomization to the hypothermia group, cold saline
was started after a mean of 7 min and endovascular cooling
after a mean of 30 min. Mean console run time before
reperfusion was 13 min. Mean saline volume was 1,325
 523 ml, infused during a mean of 28 min before reper-
fusion. Hypothermia treatment caused an increase in
randomization-to-balloon time of 9 min, from 33.3  21.2
min to 42.7  16.6 min. Mean temperature at reperfusion
was 34.7  0.6C (Fig 1). At the time of reperfusion, core
body temperatures 35C were achieved in 76% of patients,
and core body temperatures 35.4C were achieved in 91%
of the patients randomized to hypothermia. Cold saline and
endovascular cooling were successfully used in 60 of the
61 patients. Intravenous meperidine was administered in
the catheterization laboratory to prevent shivering in all
patients in the hypothermia group, with a mean total dose of
114  67 mg. Buspirone was administered to 71% of the
patients. One control patient received hypothermia in error.
This patient also lacked CMR data.Assessment of IS and MaR. CMR data were missing for
19% of the patients, equally distributed between the groups.
The reasons for missing CMR data were claustrophobia
(n ¼ 6), CMR not available or image quality unsatisfactory
(n ¼ 6), patient not willing (n ¼ 6), CMR disrupted by
patient decision (e.g., chronic back pain) (n ¼ 3), incorrect
randomization (n ¼ 1), and rib fracture after cardiopulmo-
nary resuscitation (n ¼ 1). There was no difference between
the hypothermia and control groups with regard to the
timing of the CMR examination (4.0  1.4 days vs. 3.7 
1.5 days, respectively).
The median IS normalized to MaR (the primary end
point) was 40.5% (interquartile range [IQR]: 29.3% to
57.8%) in the hypothermia group and 46.6% (IQR: 37.8%
to 63.4%) in the control group, with a relative reduction of
13% and an absolute reduction of 5.5% (95% conﬁdence
interval: 2.0% to 12.9%; p ¼ 0.15) (Fig. 2, Table 2).
Adjustment for investigational site resulted in a p value of
0.27. MaR as a percent of left ventricular mass was similar
between treatment groups: 34.6% (IQR: 28.7% to 43.8%)
and 34.9% (IQR: 29.1% to 44.8%) in the hypothermia and
control groups, respectively.
The relative reduction in IS normalized to MaR in
anterior infarcts (predeﬁned subgroup) was 27% (43.7%
[IQR: 37.8% to 64.3%] vs. 59.9% [IQR: 46.2% to 67.3%],
hypothermia [n ¼ 15] vs. control [n ¼ 21]; p ¼ 0.22)
(Fig. 3). The relative reduction in IS normalized to MaR in
inferior infarcts was 9% (36.6% [IQR: 9.2% to 75.8%] vs.
40.6% [IQR: 26.6% to 58.8%], hypothermia [n ¼ 34] vs.
control [n ¼ 26]; p ¼ 0.74). The p value for interaction by
infarct location was 0.48. Exploratory analysis of early
Figure 2 IS as a Percent of MaR
Infarct size (IS) as a percent of myocardium at risk (MaR) by treatment (median,
interquartile range, and 95% conﬁdence interval). RR ¼ relative risk reduction.
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tion of 33% (40.9% [IQR: 32.6% to 57.7%] vs. 60.9% [IQR:
46.1% to 68.0%]; p ¼ 0.046) (Fig. 4, Table 2).
When comparing only cooled patients who did achieve
the target temperature of 35C, there was still no signiﬁ-
cant difference IS/MaR, but the importance of temperature
was difﬁcult to evaluate, because all patients were in a narrow
temperature window, with only 24% at >35C and only 9%
at >35.4C (Table 2). In an exploratory analysis by sex,
women had a numerical absolute increase of 1.4%, whereas
men had a numerical absolute reduction of 6.2%. The
p value for interaction by sex was 0.45. There was no dif-
ference according to full-analysis set or per-protocol set.
There was no difference according to TIMI grade 0 or
TIMI grades 1 to 3 (Table 2).
Clinical events and safety. Combination hypothermia was
well tolerated in all patients. PCI operators and nurses
found the protocol easy to implement. The primary clinical
end point of adjudicated death and heart failure was
signiﬁcantly reduced in the hypothermia group at 45 days
(2 vs. 8 events, p ¼ 0.047) (Fig. 5). Heart failure was
present only in patients with anterior infarcts. Because
there was no mortality in either group, the reduction in
events consisted entirely of fewer adjudicated heart failure
events.
There were no differences in rates of pneumonia, ven-
tricular arrhythmias, bradycardia, reinfarction, stroke, and
major bleeding between the groups (Table 3).
Other endpoints. Microvascular obstruction as a percent of
the left ventricle was similar between the hypothermia andTable 2 Infarct Size in Relation to Myocardium at Risk in the Total P
Hypothermia
n Median (IQR)
Full-analysis set 49 40.6 (29.3 to 57.8)
Per-protocol set* 49 40.6 (29.3 to 57.8)
35C set* 38 40.9 (29.3 to 57.6)
TIMI ﬂow grade before PCI*
0 39 48.4 (32.8 to 61.3)
1–3 10 25.0 (16.6 to 38.2)
Infarct location*
Anterior 15 43.7 (37.8 to 64.3)
Inferior 34 36.7 (28.3 to 57.5)
Time from symptom onset to reperfusion (h)
0–4 42 40.5 (28.3 to 57.6)
>4 7 61.6 (35.8 to 64.3)
Infarct location and time from
symptom onset to reperfusion (h)
Anterior, 0–4 12 40.9 (34.3 to 57.7)
Anterior, >4 3 64.3 (64.3 to 66.6)
Inferior, 0–4 30 38.0 (28.3 to 57.5)
Inferior, >4 4 36.7 (27.7 to 49.5)
Sex
Male 40 42.4 (31.7 to 58.4)
Female 9 28.3 (23.2 to 48.4)
*Pre-deﬁned subgroup. yp value for effect. zp value for interaction. xCenter-adjusted p ¼ 0.28.
CI ¼ conﬁdence interval; IQR ¼ interquartile range; other abbreviations as in Table 1.control groups: 0.24% (IQR: 0% to 9.35%) versus 0.12%
(IQR: 0% to 5.25%). Ejection fraction analyzed by CMR
at 4  2 days did not differ: 50% (IQR: 42% to 53%) inopulation and Subgroups
Control
Mean Difference (95% CI) p Valuen Median (IQR)
48 46.6 (37.8 to 63.4) 5.45 (12.94 to 2.04) 0.15yx
47 46.8 (37.7 to 64.2) 5.58 (13.15 to 1.99) 0.15y
48 46.6 (37.8 to 63.4) 6.16 (14.13 to 1.81) 0.13y
35 53.2 (40.4 to 64.4) 4.64 (12.70 to 3.41) 0.35z
13 33.6 (26.2 to 60.9) 12.55 (27.09 to 2.00)
21 60.0 (46.2 to 67.4) 7.50 (19.58 to 4.58) 0.48z
26 40.7 (26.6 to 58.8) 2.01 (11.32 to 7.30)
40 51.6 (39.0 to 64.5) 8.48 (16.60 to 0.36) 0.068z
7 38.0 (26.2 to 58.8) 11.28 (8.37 to 30.92)
19 60.9 (46.2 to 68.0) 12.47 (25.67 to 0.74) 0.29z
2 46.8 (33.6 to 60.0) 18.27 (14.41 to 50.96)
20 44.6 (27.0 to 61.0) 3.63 (13.97 to 6.71)
5 38.0 (26.2 to 38.4) 3.18 (20.83 to 27.20)
41 53.2 (38.4 to 64.2) 6.24 (14.27 to 1.78) 0.45z
7 26.2 (20.7 to 49.9) 1.38 (16.82 to 19.58)
Figure 3 IS by Infarct Location
Predeﬁned subgroup analysis of infarct size (IS) as a percent of myocardium at risk (MaR) by treatment and location, full-analysis set (median, interquartile range,
and 95% conﬁdence interval). (A) Inferior ST-segment elevation myocardial infarction (STEMI) (control, n ¼ 26; hypothermia, n ¼ 34; p ¼ 0.76). (B) Anterior STEMI
(control, n ¼ 21; hypothermia, n ¼ 15; p ¼ 0.22). RR ¼ relative risk reduction.
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the control group (Table 4).
ST-segment resolution at 1.5 h after reperfusion was
numerically more pronounced in hypothermia-treated
patients (83.0% [IQR: 66.7% to 92.9%] vs. 75.7% [IQR:
57.1% to 88.9%], hypothermia vs. control; p ¼ 0.13). In
a post-hoc analysis, ST-segment elevation at 1.5 h was
signiﬁcantly lower in hypothermia-treated patients (2.0 mm
[IQR: 0.5 to 5.0 mm] vs. 3.5 mm [IQR: 1.0 to 7.0 mm],
hypothermia vs. control; p ¼ 0.047) (Table 4).
The area under the curve or peak concentration for
troponin T or creatine kinase-MB did not differ between theFigure 4 Exploratory Analysis of Early Infarctions (Symptom-to-Ballo
(A) All patients, 0 to 4 h (control, n ¼ 39; hypothermia, n ¼ 42; p ¼ 0.049). (B) All pati
(C) All patients with anterior STEMIs, 0 to 4 h (control, n ¼ 19; hypothermia, n ¼ 12; p ¼groups. N-terminal pro–brain natriuretic peptide at 4  2
days was also similar between the groups (Table 4).
Discussion
In this prospective, multicenter, randomized trial in patients
with STEMIs, hypothermia using intravenous cold saline
and an endovascular venous cooling catheter was safe,
feasible, and easy to implement and reduced body temper-
ature to 34.7C before reperfusion, with a delay of reper-
fusion of 9 min. The primary end point of IS in relation to
MaR was not signiﬁcantly reduced. The key clinical endon Time 0 to 4 h)
ents with inferior STEMIs, 0 to 4 h (control, n ¼ 20; hypothermia, n ¼ 30; p ¼ NS).
0.046). IS ¼ infarct size; MaR ¼ myocardium at risk; RR ¼ relative risk reduction.
Figure 5 Death and Heart Failure
Main clinical end point of death and heart failure at day 45. There were no deaths.
Heart failure events were monitored and adjudicated by a blinded central adjudi-
cation committee.
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(driven by heart failure events). In further exploratory ana-
lyses, there was a suggestion that anterior STEMI of short
duration may be the type of STEMI that beneﬁts
from hypothermia therapy, but this needs to be conﬁrmed
in a future trial.
Safety. The safety of using endovascular cooling alone
has previously been demonstrated in awake patients with
AMIs (13,14,22). The rationale of using a combination
of cold saline together with endovascular cooling was to
achieve a rapid induction of hypothermia as early as possible
during the ischemic period without delaying reperfusion
therapy. However, an intravenous infusion of cold saline
could possibly lead to an increase in acute heart failure and
pulmonary congestion in patients with AMIs. In this pop-
ulation without previous congestive heart failure on pre-
sentation, despite large myocardial infarctions, clinical signs
of heart failure were reduced in the hypothermia group.
There was no difference in rates of pneumonia, ventricular
arrhythmias, bradycardia, reinfarction, stroke, or majorTable 3 Clinical Events at Day 45  15
Outcome at 45 Days
Hypothermia
(n ¼ 61)
Control
(n ¼ 59)
Mortality 0 (0) 0 (0)
Heart failure 2 (3%) 8 (14%)
Reinfarction 1 (2%) 0 (0%)
VT/VF 5 (8%) 2 (3%)
Atrial ﬁbrillation/ﬂutter 4 (6%) 4 (7%)
Stroke 0 (0) 0 (0)
Pneumonia 3 (5%) 1 (2%)
Pulmonary edema 1 (2%) 2 (3%)
Major bleeding 0 (0%) 1 (2%)
Bradycardia 2 (3%) 1 (2%)
Values are n (%). p ¼ NS for all comparisons except heart failure (p < 0.05).
VF ¼ ventricular ﬁbrillation; VT ¼ ventricular tachycardia.bleeding between the groups, and most important, there
were no deaths in either group, indicating that the therapy is
safe.
Feasibility. In a previous experimental study, it was
demonstrated that a combination of cold saline infusion and
an endovascular cooling catheter can accomplish a reduction
in core body temperature to 35C within 5 to 10 min in
pigs weighing 40 to 50 kg (10). In the present study,
inducing hypothermia with a combination of cold saline
infusion and endovascular cooling was clinically feasible and
achieved a rapid reduction in core body temperature in pa-
tients with STEMIs, without a major delay in time to
reperfusion (9 min). In patients randomized to hypothermia,
76% reached 35C and 91% reached 35.4C, with only
14 min of catheter cooling. Lower temperatures at the time
of reperfusion reduce IS even further in animal models (11),
and efforts to achieve a lower temperature before reperfusion
could result in further IS reduction.
Meperidine and buspirone were chosen to suppress
shivering because they act synergistically without causing
respiratory depression (23). Furthermore, the drugs have
been used in previous clinical trials with high tolerance in
awake patients with AMIs (13,14). In this study, hypo-
thermia was well tolerated, and treatment was not dis-
continued in any patients because of shivering.
IS. Using CMR to assess IS in relation to MaR has re-
cently been validated in patients with AMIs (18,19,24) and
used to describe the natural course of infarct evolution in
humans (25). This method reduces the sample size needed
in clinical trials to show signiﬁcant effects of cardioprotec-
tive interventions. Therapeutic hypothermia numerically
reduced IS/MaR by 13% but did not reach signiﬁcance.
This is in contrast to a large number of highly reproducible
animal experiments in many species (11). To try to under-
stand the effects of hypothermia in humans, we performed
predeﬁned analyses of IS/MaR subgroups. TIMI ﬂow grade,
temperature, and sex did not signiﬁcantly inﬂuence the
results. However, similar to the ICE-IT and COOL-MI
(Cooling as an Adjunctive Therapy to Percutaneous
Intervention in Patients With Acute Myocardial Infarc-
tion) trials, the anterior STEMI subgroup seemed to
beneﬁt more, with an IS reduction of 27%. This was
further pronounced in early anterior STEMI, with an IS
reduction of 33%. In this group, absolute reduction of IS
as a percent of the left ventricle was numerically reduced by
6.2%, which seems comparable with the 5.1% absolute
reduction in IS in the STOPAMI (Stent Versus Throm-
bolysis for Occluded Coronary Arteries in Patients With
Acute Myocardial Infarction) trial, which is now accepted
as a clinically meaningful result for cardioprotection trials
(26). It would therefore be logical to further explore the
potential cardioprotective effects of hypothermia in a new
study focusing only on anterior STEMI of short duration
(<4 h from symptom onset to PCI), especially in light of
the several cardioprotection studies previously focusing on
this subset of patients with STEMIs (27,28).
Table 4 Cardiac MRI, Biomarker, ECG, and Angiographic End Points
Outcome Hypothermia Control Treatment Contrast (95% CI)* p Value
Microvascular obstruction size at 4  2 days, % of left ventricle 0.26 (0 to 9.35) 0.12 (0 to 5.25) 0.46 (2.87 to 3.79) 0.79
Left ventricular ejection fraction at 4  2 days,
% of end-diastolic volume
50 (42 to 53) 51 (43 to 56) 1.46 (4.82 to 1.91) 0.39
Hs troponin T, 48-h AUC, arbitrary units 137,626 (158) 137,468 (123) 0.99 (0.68 to 1.43) 0.96
Hs troponin T, peak concentration, ng/l 4,686 (178) 4,787 (135) 0.97 (0.65 to 1.43) 0.87
CK-MB, 48-h AUC, arbitrary units 4,281 (107) 3,877 (99) 1.09 (0.80 to 1.47) 0.59
CK-MB, peak concentration, mg/l 219.1 (136) 191.7 (115) 1.13 (0.80 to 1.59) 0.50
NT-proBNP at 4  2 days, ng/l 834.2 (115) 637.9 (153) 1.26 (0.88 to 1.82) 0.21
ST-segment resolution 1.5 h after opening the IRA, % of initial elevation 83.0 (66.7 to 92.9) 75.7 (57.1 to 88.9) 5.6 (0.8 to 13.2) 0.13
ST-segment elevation 1.5 h after opening the IRA, mmy 2.0 (0.5 to 5.0) 3.5 (1.0 to 7.0) 1.0 (2.0 to 0.0) 0.04
Patients with at least 50% ST-segment resolution 49 (84%) 50 (86%) 0.87 (0.27 to 2.8) 1.00
TIMI ﬂow grade after PCI 0.27
2 2 (3%) 5 (8%)
3 57 (93%) 53 (90%)
Percent stenosis after PCI 0 (0 to 0) 0 (0 to 0) 0 (0 to 0) 0.97
Values are median (interquartile range), geometric mean (%CV), or n (%). *Microvascular obstruction and ejection fraction: mean difference and p value from unadjusted linear model. Heart failure and 50%
ST-segment resolution: exact odds ratio and Fisher’s exact test. Biomarkers: geometric mean ratio and p value from log-linear model adjusted for center. ST-segment elevation and resolution and percent
stenosis: Hodges-Lehmann estimate of location shift and Wilcoxon test. TIMI ﬂow: exact Wilcoxon test. yPost-hoc analysis.
AUC ¼ area under the curve; CK-MB ¼ creatine kinase–MB; ECG ¼ electrocardiographic; Hs ¼ high-sensitivity; IRA ¼ infarct-related artery; MRI ¼ magnetic resonance imaging; NT-proBNP ¼ N-terminal
pro–brain natriuretic peptide; other abbreviations as in Table 1.
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nation of death and heart failure, was signiﬁcantly reduced in
the therapeutic hypothermia group, explained solely by a
reduction in heart failure, as there were no deaths in either
arm. Because all the heart failure events occurred in patients
with anterior STEMIs, the reduction in heart failure could
be the result of a more pronounced reduction in IS in pa-
tients with anterior STEMIs. However, there were also
more anterior STEMIs in the control group, which may
have inﬂuenced the results. There was also a trend toward
better ST-segment resolution and reduced ST-segment
levels at 1.5 h in the hypothermia group. However, we did
not see any difference in cardiac biomarkers, pro–brain
natriuretic peptide, microvascular obstruction, or ejection
fraction. All of these surrogate parameters are known to have
larger variability than IS/MaR and are difﬁcult to evaluate.
Study limitations. The patients were not at high risk, as
patients older than 75 years, those in Killip classes II to IV,
and those with cardiac arrest were excluded. It cannot be
excluded that part of the hyperenhanced myocardium on
CMR acquired at 4  2 days may have been due to edema,
as it has recently been shown that there is a signiﬁcant
decrease in hyperenhanced myocardium during the ﬁrst
week after infarction (29). There was, however, no difference
in the timing of the CMR examination between the hypo-
thermic patients and the controls. Furthermore, area at risk
was similar between the treatment groups. CMR data were
missing for 19% of the patients, equally distributed between
the groups and of similar magnitude as observed in other
CMR-based trials (27). The exploratory and secondary an-
alyses should be evaluated with caution because they are at
risk for type 1 error.Conclusions
The results of this study show that although hypothermia
induced using a combination of cold saline infusion and
endovascular cooling before reperfusion in awake patients
with STEMIs was feasible and safe, with only a small delay
time to reperfusion, it did not signiﬁcantly reduce IS. The
clinical end point of adjudicated heart failure was signiﬁ-
cantly reduced in the hypothermia group. Exploratory ana-
lyses suggested that anterior STEMI of short duration still
might beneﬁt from the treatment, which warrants further
evaluation in future trials.
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APPENDIX
For an additional description of the methods, please see the online version
of this article.
